| pubmed-article:8977271 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C1623048 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C1883036 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C1145667 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C0486805 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C2825311 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C2349209 | lld:lifeskim |
| pubmed-article:8977271 | lifeskim:mentions | umls-concept:C1513311 | lld:lifeskim |
| pubmed-article:8977271 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:8977271 | pubmed:dateCreated | 1997-2-4 | lld:pubmed |
| pubmed-article:8977271 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8977271 | pubmed:abstractText | Several antibody-dependent mechanisms have been postulated to mediate neutralization of different animal viruses, including blocking of docking to receptors, induction of conformational changes in the virus coat, and Fc-dependent opsonization. We have studied the molecular requirements for antibody-mediated neutralization of vesicular stomatitis virus (VSV) in vitro and protection against lethal disease in vivo with a single-chain Fv fragment (scFv) and the corresponding bivalent miniantibody (scFv-dHLX) generated from a VSV-neutralizing monoclonal antibody. Both monovalent scFv and bivalent scFv-dHLX miniantibodies were able to neutralize VSV in vitro and to protect interferon-alphabeta receptor-deficient (IFN-alphabeta R-/-) mice against lethal disease after intravenous injection of 50 plaque-forming units (pfu) VSV pre-incubated with the scFv reagents. Similarly, severe-combined immunodeficient (SCID) mice infected with immune complexes of 10(8) pfu VSV and bivalent scFv-dHLX were protected against lethal disease; however, mice infected with immune complexes of 10(8) pfu VSV and monovalent scFv were not. Although repeated scFv-dHLX treatment reduced virus quantities in the blood, neither SCID nor IFN-alphabeta R-/- mice were protected against lethal disease after passive immunization and subsequent VSV infection. This was due to the short half-life of 17 min of scFv-dHLX in the circulation. These data demonstrate that neutralization of VSV and protection against lethal disease do not require Fc-mediated mechanisms and that cross-linking is not crucial for protection against physiologically relevant virus doses in vivo. | lld:pubmed |
| pubmed-article:8977271 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8977271 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8977271 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8977271 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8977271 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8977271 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8977271 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8977271 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8977271 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:8977271 | pubmed:issn | 0014-2980 | lld:pubmed |
| pubmed-article:8977271 | pubmed:author | pubmed-author:ZinkernagelR... | lld:pubmed |
| pubmed-article:8977271 | pubmed:author | pubmed-author:HengartnerHH | lld:pubmed |
| pubmed-article:8977271 | pubmed:author | pubmed-author:BucherEE | lld:pubmed |
| pubmed-article:8977271 | pubmed:author | pubmed-author:PlückthunAA | lld:pubmed |
| pubmed-article:8977271 | pubmed:author | pubmed-author:KalinkeUU | lld:pubmed |
| pubmed-article:8977271 | pubmed:author | pubmed-author:KrebberCC | lld:pubmed |
| pubmed-article:8977271 | pubmed:author | pubmed-author:KrebberAA | lld:pubmed |
| pubmed-article:8977271 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8977271 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:8977271 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8977271 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8977271 | pubmed:pagination | 2801-6 | lld:pubmed |
| pubmed-article:8977271 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:meshHeading | pubmed-meshheading:8977271-... | lld:pubmed |
| pubmed-article:8977271 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8977271 | pubmed:articleTitle | Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. | lld:pubmed |
| pubmed-article:8977271 | pubmed:affiliation | Institute of Experimental Immunology, Department of Pathology, University of Zürich, Switzerland. ukalinke@usz.unizh.ch | lld:pubmed |
| pubmed-article:8977271 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8977271 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8977271 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8977271 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8977271 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8977271 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8977271 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8977271 | lld:pubmed |
